Home / Health / Retatrutide: The Next Generation of Weight Loss?
Retatrutide: The Next Generation of Weight Loss?
21 May
Summary
- Retatrutide activates three hormone receptors for weight loss.
- It offers potential for significant weight reduction with fewer side effects.
- Unregulated online peptides carry risks of bacterial toxins.
A new investigational drug, retatrutide, is emerging as a potential advancement in weight loss therapies by acting as a triple agonist. Unlike earlier GLP-1 medications that could lead to substantial muscle loss due to rapid caloric deficits, retatrutide targets three hormone receptors: GIP, GLP-1, and glucagon. This multi-receptor approach is reported to offer a lower side effect profile and a muscle-sparing effect.
Administered as a once-weekly subcutaneous injection in clinical trials, retatrutide aims to facilitate up to a third of body weight loss over approximately one year. Despite its promise, the drug is still under evaluation by its manufacturer and is not yet approved by regulatory agencies. Its investigational nature has spurred a thriving gray market for peptides sold online and through compounding pharmacies.
Experts, including neuroscientist Dr. Andrew Huberman, strongly caution against these unregulated sources. They highlight the risk of contamination with bacterial toxins like lipopolysaccharides (LPS) in products claiming high purity. Such toxins can cause inflammation, potentially leading to serious health issues with repeated use. Both experts and the manufacturer stress that retatrutide is legally available only through clinical trials.
